{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:53:45Z","timestamp":1769630025870,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009610","name":"Pontificia Universidad Cat\u00f3lica de Chile","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jcv.2020.104657","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:15:43Z","timestamp":1602022543000},"page":"104657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia"],"prefix":"10.1016","volume":"132","author":[{"given":"Camila","family":"Villalobos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-6485","authenticated-orcid":false,"given":"Mar\u00eda Elena","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Ferr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2020.104657_bib0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcv.2004.11.006","article-title":"Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART","volume":"33","author":"Chew","year":"2005","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2020.104657_bib0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4067\/S0716-10182016000500007","article-title":"Virological and immunological outcomes to antiretroviral therapy in HIV-infected patients of an academic medical center in Chile","volume":"33","author":"Ceballos","year":"2016","journal-title":"Rev. Chil. Infectolog\u00e3\u00ada"},{"key":"10.1016\/j.jcv.2020.104657_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","article-title":"Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients","volume":"29","author":"Antiretroviral Therapy Cohort Collaboration (ART-CC)","year":"2015","journal-title":"AIDS."},{"key":"10.1016\/j.jcv.2020.104657_bib0020","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/QAI.0000000000001678","article-title":"CoRIS Study Group, Low-Level Viremia Is Associated With Clinical Progression in HIV-Infected Patients Receiving Antiretroviral Treatment","volume":"78","author":"Bernal","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2020.104657_bib0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104657_bib0030","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cid\/ciu019","article-title":"Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals","volume":"58","author":"Gonzalez-Serna","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104657_bib0035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1086\/651618","article-title":"Antiretroviral drug resistance in HIV\u20101\u2010Infected patients with low\u2010level viremia","volume":"201","author":"Mackie","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104657_bib0040","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1128\/AAC.01217-12","article-title":"Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia","volume":"56","author":"Li","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2020.104657_bib0045","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/QAD.0000000000000203","article-title":"HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure","volume":"28","author":"Swenson","year":"2014","journal-title":"AIDS."},{"key":"10.1016\/j.jcv.2020.104657_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036673","article-title":"Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients","volume":"7","author":"Delaugerre","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2020.104657_bib0055","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. (n.d.). Available at: http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/ AdultandAdolescentGL.pdf. Accessed February 20, 2020 (accessed May 3, 2020)."},{"key":"10.1016\/j.jcv.2020.104657_bib0060","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1128\/JCM.41.4.1594-1599.2003","article-title":"Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System, J","volume":"41","author":"Kuritzkes","year":"2003","journal-title":"Clin. Microbiol."},{"key":"10.1016\/j.jcv.2020.104657_bib0065","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1293.2009.00814.x","article-title":"HIV-1 proviral resistance mutations: usefulness in clinical practice","author":"Kabamba-Mukadi","year":"2010","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2020.104657_bib0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0213-005X(13)70112-5","article-title":"Detection of resistance mutations in proviral DNA in HIV-1 infection","volume":"31","author":"Delgado","year":"2013","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"10.1016\/j.jcv.2020.104657_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4236\/wja.2013.32010","article-title":"HIV drug resistance profiles and clinical outcomes in patients with viremia maintained at very low levels","volume":"3","author":"Jordan","year":"2013","journal-title":"World J. AIDS"},{"key":"10.1016\/j.jcv.2020.104657_bib0080","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","article-title":"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels","volume":"58","author":"Santoro","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104657_bib0085","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3851\/IMP2966","article-title":"Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART","volume":"20","author":"Vancoillie","year":"2015","journal-title":"Antivir. Ther. (Lond.)"},{"key":"10.1016\/j.jcv.2020.104657_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2019.104255","article-title":"How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis","volume":"123","author":"Taramasso","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2020.104657_bib0095","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1128\/AAC.01490-15","article-title":"HIV Drug Resistance Testing by High-Multiplex \u201cWide\u201d Sequencing on the MiSeq Instrument","volume":"59","author":"Lapointe","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2020.104657_bib0100","unstructured":"HIV Drug Resistance Database, (n.d.). https:\/\/hivdb.stanford.edu\/hivdb\/by-mutations\/report\/ (accessed April 2019)."},{"key":"10.1016\/j.jcv.2020.104657_bib0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/QAI.0b013e3182745ab0","article-title":"Low-level HIV viremia is associated with microbial translocation and inflammation","volume":"62","author":"Reus","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jcv.2020.104657_bib0110","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11904-017-0356-x","article-title":"Inflammation, immune activation, and antiretroviral therapy in HIV","volume":"14","author":"Hileman","year":"2017","journal-title":"Curr. HIVAIDS Rep."},{"key":"10.1016\/j.jcv.2020.104657_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117430","article-title":"HIV drug resistance mutations in proviral DNA from a community treatment program","volume":"10","author":"Derache","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2020.104657_bib0120","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4172\/2155-6113.1000141","article-title":"Comparing peripheral blood mononuclear cell DNA and circulating plasma viral RNA pol genotypes of subtype C HIV-1","volume":"3","author":"Banks","year":"2012","journal-title":"J. AIDS Clin. Res."},{"key":"10.1016\/j.jcv.2020.104657_bib0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431093","article-title":"Proviral DNA as a Target for HIV-1 Resistance Analysis","volume":"58","author":"L\u00fcbke","year":"2015","journal-title":"Intervirology."},{"key":"10.1016\/j.jcv.2020.104657_bib0130","article-title":"HIV-1C proviral DNA for detection of drug resistance mutations","volume":"13","author":"Huruy","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2020.104657_bib0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/QAD.0b013e3283445834","article-title":"Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia","volume":"25","author":"Gallien","year":"2011","journal-title":"AIDS."},{"key":"10.1016\/j.jcv.2020.104657_bib0140","unstructured":"European AIDS Clinical Society (EACS), EACS Guidelines. Version 10.0. November 2019. (n.d.). Available at: https:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0_final.pdf (accessed May 3, 2020)."},{"key":"10.1016\/j.jcv.2020.104657_bib0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","volume":"104","author":"Armenia","year":"2018","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2020.104657_bib0150","first-page":"669","article-title":"[Prevalence of primary antiretroviral resistance among HIV infected patients in Chile]","volume":"138","author":"Afani","year":"2010","journal-title":"Rev. Med. Chil."},{"key":"10.1016\/j.jcv.2020.104657_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158560","article-title":"Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: a systematic review and meta-analysis","volume":"11","author":"Avila-Rios","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcv.2020.104657_bib0160","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3349","article-title":"Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA","author":"Bavaro","year":"2020","journal-title":"Antivir. Ther. (Lond.)"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220303991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220303991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:13:41Z","timestamp":1761362021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653220303991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"alternative-id":["S1386653220303991"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104657","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug resistance mutations in proviral DNA of HIV-infected patients with low level of viremia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104657"}}